drugset / Trial / NCT07644559
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer
RandomizedParallel-groupSingle-blindTreatment
Summary
This study will assess the safety and efficacy of VS-7375 alone and in combination with cetuximab in patients with metastatic KRAS G12D - mutated Pancreatic Cancer
Timeline
- Start
- 2026-06-16
- Primary completion
- 2027-06
- Completion
- 2028-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cetuximab | Monoclonal antibody | — | Subcutaneous |
| Subject | Panitumumab | Monoclonal antibody | — | Subcutaneous |
| Subject | VS-7375 | Small molecule | — | Oral |